Skip to main content
Open Access Publications from the University of California

Induction and characterization of lymphotoxins from tumor promoter — Synergized, lectin-stimulated human lymphocytes in vitro

  • Author(s): Klostergaard, J
  • Goodsel, D
  • Granger, GA
  • et al.
Creative Commons Attribution 4.0 International Public License

The tumor promoters mezerein and phorbol myristate acetate, and the phorbol diesters phorbol diacetate, phorbol dibenzoate, and phorbol didecanoate synergistically enhanced the production of lymphotoxin (LT) by phytohemagglutinin-stimulated human peripheral blood or tonsil and adenoid lymphocytes. LT production was elevated 2-20-fold, depending on such parameters as the nature of the promoter and dose, the lectin dose, and the lymphocyte source. The increased LT levels were primarily due to enhanced production of the alpha-light (αL) class of LT. The αL-class obtained from supernatants from promoter-synergized, lectin-stimulated lymphocyte cultures was compared with the αL from lectin-stimulated cultures. They were indistinguishable by molecular sieving on Ultrogel AcA44, were both composed primarily of the α2-subclass as determined by ion-exchange chromatography on DEAE-Sepharose, and were immunologically cross-reactive. Lectin-affinity chromatography on concanavalin A-Sepharose and on lentil-lectin-Sepharose revealed that both αL preparations were dominated by components with affinity for these matrices. Affinity chromatography on alkyl sorbents also indicated very similar hydrophobicities. Chromatofocusing of the αL preparations demonstrated a comparable pattern of isoelectric points. Thus, the use of these drugs in lectin-stimulated human lymphocyte cultures provides an effective means for significantly increasing the yield of αL-LT suitable for biochemical purification and analysis, and biological testing in vitro. © 1985 Raven Press, New York.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View